1. Recent Articles

    1. PEST-containing nuclear protein mediates the proliferation, migration, and invasion of human neuroblastoma cells through MAPK and PI3K/AKT/mTOR signaling pathways.

      PEST-containing nuclear protein mediates the proliferation, migration, and invasion of human neuroblastoma cells through MAPK and PI3K/AKT/mTOR signaling pathways.

      BMC Cancer. 2018 May 02;18(1):499

      Authors: Wu DD, Gao YR, Li T, Wang DY, Lu D, Liu SY, Hong Y, Ning HB, Liu JP, Shang J, Shi JF, Wei JS, Ji XY

      Read Full Article
    2. The antitumor effect of static and extremely low frequency magnetic fields against nephroblastoma and neuroblastoma.

      The antitumor effect of static and extremely low frequency magnetic fields against nephroblastoma and neuroblastoma.

      Bioelectromagnetics. 2018 May 02;:

      Authors: Yuan LQ, Wang C, Zhu K, Li HM, Gu WZ, Zhou DM, Lai JQ, Zhou D, Lv Y, Tofani S, Chen X

      Abstract Certain magnetic fields (MF) have potential therapeutic antitumor effect whereas the underlying mechanism remains undefined.

      Read Full Article
    3. MicroRNA-193b-3p represses neuroblastoma cell growth via downregulation of Cyclin D1, MCL-1 and MYCN.

      MicroRNA-193b-3p represses neuroblastoma cell growth via downregulation of Cyclin D1, MCL-1 and MYCN.

      Oncotarget. 2018 Apr 06;9(26):18160-18179

      Authors: Roth SA, Hald ØH, Fuchs S, Løkke C, Mikkola I, Flægstad T, Schulte J, Einvik C

      Abstract Neuroblastoma is the most common diagnosed tumor in infants and the second most common extracranial tumor of childhood. The survival rate of patients with high-risk neuroblastoma is still very low despite intensive multimodal treatments.

      Read Full Article
      Mentions: MYCN
    4. Autophagy inhibition improves the cytotoxic effects of receptor tyrosine kinase inhibitors.

      Autophagy inhibition improves the cytotoxic effects of receptor tyrosine kinase inhibitors.

      Cancer Cell Int. 2018;18:63

      Authors: Aveic S, Pantile M, Polo P, Sidarovich V, De Mariano M, Quattrone A, Longo L, Tonini GP

      Abstract Background: A growing field of evidence suggests the involvement of oncogenic receptor tyrosine kinases (RTKs) in cell transformation.

      Read Full Article
    5. Targeted Doxorubicin-Loaded Bacterially Derived Nano-Cells for the Treatment of Neuroblastoma

      Targeted Doxorubicin-Loaded Bacterially Derived Nano-Cells for the Treatment of Neuroblastoma

      Advanced stage neuroblastoma is an aggressive disease with limited treatment options for patients with drug-resistant tumors. Targeted delivery of chemotherapy for pediatric cancers offers promise to improve treatment efficacy and reduce toxicity associated with systemic chemotherapy. The EnGeneIC Dream Vector (EDVTM) is a nanocell, which can package chemotherapeutic drugs and target tumors via attachment of bispecific proteins to the surface of the nanocell.

      Read Full Article
    6. Targeting of epigenetic regulators in neuroblastoma.

      Targeting of epigenetic regulators in neuroblastoma.

      Exp Mol Med. 2018 Apr 27;50(4):51

      Authors: Jubierre L, Jiménez C, Rovira E, Soriano A, Sábado C, Gros L, Llort A, Hladun R, Roma J, Toledo JS, Gallego S, Segura MF

      Abstract Approximately 15,000 new cases of pediatric cancer are diagnosed yearly in Europe, with 8-10% corresponding to neuroblastoma, a rare disease with an incidence of 8-9 cases per million children <15 years of age.

      Read Full Article
    7. Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).

      Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).

      Int J Clin Oncol. 2018 Apr 26;:

      Authors: Hishiki T, Matsumoto K, Ohira M, Kamijo T, Shichino H, Kuroda T, Yoneda A, Soejima T, Nakazawa A, Takimoto T, Yokota I, Teramukai S, Takahashi H, Fukushima T, Kaneko T, Hara J, Kaneko M, Ikeda H, Tajiri T, Nakagawara A, Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG)

      Read Full Article
    8. Chromatin Immunoprecipitation and DNA Sequencing Identified a LIMS1/ILK Pathway Regulated by LMO1 in Neuroblastoma.

      Chromatin Immunoprecipitation and DNA Sequencing Identified a LIMS1/ILK Pathway Regulated by LMO1 in Neuroblastoma.

      Cancer Genomics Proteomics. 2018 May-Jun;15(3):165-174

      Authors: Saeki N, Saito A, Sugaya Y, Amemiya M, Ono H, Komatsuzaki R, Yanagihara K, Sasaki H

      Read Full Article
      Mentions: Genetics
    9. A high-content screening of anti-cancer compounds suggests the multiple tyrosine kinase inhibitor ponatinib for repurposing in neuroblastoma therapy.

      A high-content screening of anti-cancer compounds suggests the multiple tyrosine kinase inhibitor ponatinib for repurposing in neuroblastoma therapy.

      Mol Cancer Ther. 2018 Apr 25;:

      Authors: Sidarovich V, De Mariano M, Aveic S, Pancher M, Adami V, Gatto P, Pizzini S, Pasini L, Croce M, Parodi F, Cimmino F, Avitabile M, Emionite L, Cilli M, Ferrini S, Pagano A, Capasso M, Quattrone A, Tonini GP, Longo L

      Read Full Article
    10. Autologous stem cell transplantation for refractory opsoclonus myoclonus ataxia syndrome.

      Autologous stem cell transplantation for refractory opsoclonus myoclonus ataxia syndrome.

      Pediatr Blood Cancer. 2018 Apr 25;:e27110

      Authors: Johnston DL, Murray S, Irwin MS, Doyle J, Schechter T

      Abstract Opsoclonus, myoclonus, ataxia syndrome (OMA) is a severe neurologic disorder often associated with neuroblastoma. It is challenging to treat and can have long-term neurologic sequelae.

      Read Full Article
      Mentions: Refractory
    11. BAP1 induces cell death via interaction with 14-3-3 in neuroblastoma.

      BAP1 induces cell death via interaction with 14-3-3 in neuroblastoma.

      Cell Death Dis. 2018 Apr 24;9(5):458

      Authors: Sime W, Niu Q, Abassi Y, Masoumi KC, Zarrizi R, Køhler JB, Kjellström S, Lasorsa VA, Capasso M, Fu H, Massoumi R

      Abstract BRCA1-associated protein 1 (BAP1) is a nuclear deubiquitinating enzyme that is associated with multiprotein complexes that regulate key cellular pathways, including cell cycle, cellular differentiation, cell death, and the DNA damage response.

      Read Full Article
    12. Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma.

      Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma.

      Biomed Res Int. 2018;2018:1812535

      Authors: Vanichapol T, Chutipongtanate S, Anurathapan U, Hongeng S

      Abstract Neuroblastoma (NB) is the most common extracranial solid tumor in childhood with 5-year survival rate of 40% in high-risk patients despite intensive therapies.

      Read Full Article
      Mentions: Immunotherapy
    13. See all articles
  2. Comments

  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Topics in the News

    1. (3 articles) Chemotherapy
    2. (2 articles) MYCN
    3. (2 articles) Treatment
    4. (2 articles) Refractory
    5. (1 articles) Surgery
  3. Recent Quotes

    1. We continue to expand our broad array of proprietary T cell programming technologies designed to tackle specific aspects of tumour biology and we are pleased to highlight the article published in Molecular Therapy about our novel small-molecule-activated permanent off switch.
      By Christian Itin
    2. We wanted to remove an important barrier in using B cells as an antigen-presenting cell population, helping them complement or replace dendritic cells.
      By Gregory Szeto
    3. The antigen-presenting capabilities of B cells have often been underestimated, but they are being increasingly appreciated for their practical advantages in therapies.
      By Gail Bishop
    4. Our dream is to spawn out a whole class of therapies which involve taking out your own cells, telling them what to do, and putting them back into your body to fight your disease, whatever that may be.
      By Armon Sharei
    5. We envision a future system, if we can take advantage of its microfluidic nature, as a bedside or field-deployable device.
      By Armon Sharei
    6. Down the road, you could potentially get enough cells from just a normal syringe-based blood draw, run it through a bedside device that has the antigen you want to vaccinate against, and then you'd have the vaccine.
      By Gregory Szeto
    7. The problem is that unlike blood, a skin sample or even a tissue biopsy, you can't take a piece of a patient's neural system. It runs like complex wiring throughout the body and portions cannot be sampled for study.
      By Mick Bhatia
    8. Now we can take easy to obtain blood samples, and make the main cell types of neurological systems - the central nervous system and the peripheral nervous system - in a dish that is specialized for each patient.
      By Mick Bhatia
    9. If I was a patient and I was feeling pain or experiencing neuropathy, the prized pain drug for me would target the peripheral nervous system neurons, but do nothing to the central nervous system, thus avoiding non-addictive drug side effects.
      By Mick Bhatia
    10. This bench to bedside research is very exciting and will have a major impact on the management of neurological diseases, particularly neuropathic pain.
      By Akbar Panju